Shen L, Zhang X, Ji K, Lu L, Wang Q, Guan Q et al.
Lancet 2026; 407: 2542-2553.
Some 588 patients were followed for median duration of 42.7 months, with the serplulimab group having significantly longer event-free survival (hazard ratio 0.65, 95 per cent confidence interval 0.47 to 0.90, P=0.0082). Grade 3 or worse treatment-related adverse events occurred less frequently in the serplulimab group (47 per cent) when compared to the chemotherapy group (59 per cent).
Comment: Perioperative serplulimab improved event-free survival with a favorable safety profile, pending overall survival results.
Comment by Jeongyoon (Jenny) Moon, MD
.png)
.jpg){kind=logo}
